Ironwood Pharmaceuticals, Inc. (IRWD) reported adjusted earnings of 2 cents per share for the third quarter of 2024, missing the Zacks Consensus Estimate of 9 cents. The company had recorded adjusted earnings of 12 cents per share in the year-ago quarter.Total revenues in the third quarter were $91.6 million, which beat the Zacks Consensus Estimate of $89 million. However, the top line decreased almost 19.4% year over year due to the decrease in collaborative arrangements revenues related to its sole market ...

Ironwood Pharmaceuticals Q3 2024 Investor Update November 7, 2024 1 | --- | --- | |--------------|-------| | | | | | | | | | | | | | | | | | | | | | | Introduction | | | | | | Matt Roache | | | | | | | | | | | | | | | | | | | 2 | Safe Harbor Statement 3 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2024 Earnings Call Transcript November 7, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Conference Call Participants Amy Li - Jefferies David Amsellem - Piper Sandler Jason Butler - Citizens JMP Mohit Bansal - Wells Fargo Operator Thank you for standing by. My name is Louella, and I wi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-3 ...

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -77.78%. A quarter ago, it was expected that this drugmaker would post earnings of $0.17 per share when it actually produced break-even earnings, delivering a surprise of -100%.Over the last four quarters, ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reports Third Quarter 2024 Results – LINZESS (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – BOSTON, Mass., November 7, 2024 — Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to de ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Andrew Davis - Chief Business Officer Conference Call Participants David Amsellem - Piper Sandler Amy Li - Jefferies Mohit Bansal - Wells Fargo Jason Butler - Citizens JMP Tim Chiang - Capital One Ope ...

Ironwood Pharmaceuticals, Inc. (IRWD) reported break-even earnings for the second quarter of 2024 compared with the Zacks Consensus Estimate of earnings of 17 cents per share. The company had recorded adjusted earnings of 31 cents per share in the year-ago quarter. Total revenues in the second quarter were $94.4 million, which also missed the Zacks Consensus Estimate of $104 million. The top line decreased almost 12.1% year over year due to the decrease in collaborative arrangements revenues related to the ...

1 Ironwood Pharmaceuticals Q2 2024 Investor Update August 8, 2024 | --- | --- | |--------------|-------| | | | | | | | | | | | | | | | | | | | | | | Introduction | | | | | | Matt Roache | | | | | | | | | | | | | | | | | | | 2 | Safe Harbor Statement 3 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-340417 ...